Back to top

Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Trajectory and Potential $2B Peak U.S. Sales

TD Cowen analyst Phil Nadeau has maintained their bullish stance on SNDX stock, giving a Buy rating on July 22. Phil Nadeau has given his Buy ratin...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Syndax Pharmaceuticals, Inc. (SNDX)